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Abstract
Background: Depression often co-exists with non-cardiovascular morbid conditions. Whether this comorbidity
increases the risk of cardiovascular disease has so far not been studied. Thus, the aim of this study was to
determine if non-cardiovascular morbidity modifies the effect of depression on future risk of CVD.
Methods: Data was derived from the PART study (acronym in Swedish for: Psykisk hälsa, Arbete och RelaTioner:
Mental Health, Work and Relationships), a longitudinal cohort study on mental health, work and relations, including
10,443 adults (aged 20–64 years). Depression was assessed using the Major Depression Inventory (MDI) and self-
reported data on non-cardiovascular morbidity was assessed in 1998–2000. Outcomes of CVD were assessed using
the National Patient Register during 2001–2014.
Results: Both depression (HR 1.5 (95% CI, 1.1, 2.0)) and non-cardiovascular morbidity (HR 2.0 (95% CI, 1.8, 2.6)) were
associated with an increased future risk of CVD. The combined effect of depression and non-cardiovascular comorbidity
on future CVD was HR 2.1 (95%, CI 1.3, 3.4) after adjusting for age, gender and socioeconomic position. Rather similar
associations were seen after further adjustment for hypertension, diabetes and unhealthy lifestyle factors.
Conclusion: Persons affected by depression in combination with non-cardiovascular morbidity had a higher risk of CVD
compared to those without non-cardiovascular morbidity or depression alone.
Keywords: Depression, Non-cardiovascular morbidity, Cardiovascular diseases, Morbidity
Background
Depressive disorders are a major cause of the non-fatal
burden of diseases while ischemic heart disease and stroke
are major causes of death [1]. Depression is strongly asso-
ciated with other types of morbidity [2, 3]. Previous stud-
ies have shown this relation both specifically, as well as in
combination, with other disorders [4, 5]. Further, depres-
sion is reported as a consequence, as well as, a risk factor
for other morbidities [6]. For example, depression doubles
the risk of future CVD [7–9] but also 40% of myocardial
infarction patients report depression post-infarction [10].
As depression is linked both to morbidity and to CVD,
the combined effect on future risk should be paid atten-
tion to in greater depth.
Depression increases the risk of CVD [7–9]. Established
CVD-related morbidities (CVD risk factors) like hyperten-
sion and diabetes increase the risk of CVD [11]. In addition,
other kinds of non-cardiovascular morbidity [12], such as
rheumatoid arthritis [13] and osteoarthritis [14] also increase
the risk of CVD [15]. Non-cardiovascular morbidity is a rela-
tively new term, defined as comorbidities which are not
established risk factors for CVD [16]. Generally, it includes
respiratory, endocrine, nutritional, renal, hematopoietic,
neurological as well as musculoskeletal conditions [17–19].
The number of comorbidities, and more importantly non-
cardiovascular morbidities, have been reported to increase
the severity of CVD (specifically heart failure) and this has
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been considered an important marker of prognosis in pa-
tients with heart failure [20, 21].
Depressive disorders are roughly two-times more preva-
lent among persons with diabetes, coronary artery disease,
HIV infection, and stroke compared to persons not suffer-
ing from these diseases [6]. Further, approximately 12–
15% of persons with multiple comorbid conditions also
suffer from depression [22]. Coexistence of depression
and other morbidities can lead to overexpression of som-
atic symptoms, like fatigue, thus complicating the diagno-
sis of depression [23]. Additionally, persons with
depressive disorders exhibit reduced self-efficacy and “will
to function” which might contribute to poor medication
adherence and unhealthy lifestyle factors [24]. This results
in reduced quality of life, higher costs, and worse health
outcomes and requires extensive coordination across vari-
ous sectors of the health services [3, 25].
The effect of the coexistence of depression and non-
cardiovascular morbidity on the risk of CVD, has to our
knowledge, been paid less attention. It can be hypothe-
sized that the metabolic or immune-inflammatory path-
ways might be triggered in depressed patients by
additional comorbid conditions which in turn affect the
incidence of CVD [26]. This multifaceted coexistence of
depression, other somatic and psychiatric morbidity and
CVD is a challenge to the clinical care of depressed pa-
tients and the lack of clinical guidelines on management
might lead to a worse prognosis and additional health
problems [27, 28]. Considering this, we aim to increase
the knowledge on this topic by determining if non-
cardiovascular morbidity modifies the effect of depres-
sion on future risk of CVD. In this study we hypothesize
that the risk of CVD is higher in depressed individuals
with coexisting non-cardiovascular morbidity compared
to those without.
Methods
Data was derived from the PART study, a longitudinal co-
hort study conducted in Stockholm County, Sweden [29].
This study focused on mental health, work and relations
among adults living in Stockholm. The data collection took
place in 3 waves; 1998–2000-wave 1(W1), 2001–2003-wave
2(W2) and 2010-wave 3(W3). The data was linked to the
Swedish health registers through the exclusive identifier “pin
number”. All the participants gave written informed consent
and answered a posted questionnaire. The questions focused
on risks and protective factors for mental health as well as
psychiatric rating scales. The Ethical Review Board at Karo-
linska Institutet, Stockholm, approved the study (case num-
bers 96–260, 01–218, 03–302, 2009/880–31, 2012/808–32).
The PART study initially intended to include 19,744
persons of which 19,457 could be reached, and 10,443
answered to the questionnaire at W1 (participation rate
53%). Internal missing was low due to repeated
telephone calls. Non-response analyses from W1 was
performed using available administrative registers-
showing a slightly higher response in women, higher age
groups, persons with higher income and education, be-
ing born in the Nordic countries and having no previous
psychiatric illness [30]. In W2 the participation rate was
83% (n = 8622) and similar associations were seen [31].
A description of the study population according to de-
pression status is shown in Table 1, data of 10,341 par-
ticipants were available for analysis at baseline. For the
purpose of this study participants with a current or pre-
vious history of myocardial infarction, angina or stroke
(n = 267, 2.6%) were excluded leaving a total sample of
10,074 participants.
Depression
Depression was measured as the index disease and
assessed using the Major Depression Inventory (MDI)
from W1 and W2. Participants with MDI score above 20
in either of the two waves were considered as depressed.
The MDI has shown high validity in both clinical and
non-clinical samples, including the PART study [32–34].
Non-cardiovascular morbidity
Non-cardiovascular conditions [35, 36] were derived
from self-reports asking the following question; Indicate
if you are presently or previously been diagnosed or
treated by a doctor or hospitalized for any of the follow-
ing conditions? neurological disorders (brain disease,
spinal cord, nerve fibers, headache), endocrinological
disorders (goiter, thyroid disease or metabolic disease),
respiratory disorders (asthma, chronic bronchitis or
other lung disease), gastrointestinal disorders (dyspepsia,
bowel or liver disease), kidney or urinary tract disorders,
genital disorders, serious infections, tumors (benign or
malignant), rheumatological disorders, other heart dis-
eases (except ischemic heart diseases), severe skin disor-
ders and psychiatric disorders (other than depression).
Presence of any of these was considered as non-
cardiovascular morbidity.
Cardiovascular disease
Cardiovascular disease (CVD) was evaluated using hos-
pital discharge diagnoses classified according to the
International Classification of Disease (ICD) in the Na-
tional Patient Register (NPR) during 2001 to 2014, in-
cluding the following diagnoses [37, 38]: ischemic/
hypertensive heart disease; hypertensive diseases (ICD10:
I11–13), ischemic heart diseases (ICD10: I20–25), heart
failure (ICD10: I50), other peripheral vascular diseases,
embolism and thrombosis (ICD10: I73–74) and stroke
(ICD10: I60–67 and I69).
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Covariates
Age, gender, socioeconomic position (SEP) [39], hyperten-
sion, diabetes, smoking, hazardous alcohol use, body mass
index (BMI) and physical inactivity were considered as co-
variates [40–42]. Physical inactivity and smoking were
only recorded in W2 and hence have slightly higher levels
of missing values. Age was divided into four categories:
20–30, 31–40, and 41–52 and > 52 years. SEP was mea-
sured by using the Nordic Standard Occupational
Classification (NSOC) of 1989 and classified into five
groups according to Statistics Sweden’s Goldthorpe-
Eriksson classification scheme: high/intermediate level sal-
aried employees; assistant non-manual employees; skilled
workers; unskilled workers; and self-employed (including
farmers). As a substantial number of participants (n =
2488) were not currently employed at the time of assess-
ment, we used their daily reported activity and created
additional categories; including those who were retired or
Table 1 Baseline characteristics of the participants overall, and stratified by depression status, n = 10,341
Overall Depressed Non-depressed P valuea
N = 10,341 n = 1488 n = 8832
n (%) n (%) n (%)
Age group (in years)
20–30 2595 (25.1) 432 (29.0) 2160 (24.5) < 0.001
31–40 2476 (23.9) 364 (24.5) 2102 (23.8)
41–52 2733 (26.4) 421 (28.3) 2308 (26.1)
> 52 2534 (24.5) 271 (18.2) 2259 (25.6)
Male gender 4620 (44.0) 463 (31.1) 4146 (46.9) < 0.001
Socio-economic positionb
High and intermediate level salary 4702 (45.5) 493 (37) 4206 (50.2)
Assistant –non manual workers 1438 (13.9) 222 (16.7) 1215 (14.5)
Skilled workers 665 (6.4) 94 (7.1) 570 (6.8)
Unskilled and semiskilled workers 1204 (11.6) 233 (17.5) 968 (11.6)
Self-employed (other than professional) 729 (7.0) 80 (6.0) 649 (7.7)
Students 435 (4.2) 122 (9.2) 311 (3.7)
Retired 552 (5.3) 88 (6.6) 459 (5.5) < 0.001
IHD 193 (1.9) 47 (3.2) 143 (1.6) < 0.001
Stroke 86 (0.8) 23 (1.5) 63 (0.7) 0.003
Hypertension 716 (6.9) 126 (8.5) 590 (6.7) 0.01
Diabetes mellitus 221 (2.1) 38 (2.6) 181 (2.0) 0.20
Smoking c
Regular 1289 (12.4) 306 (24.5) 983 (13.6) < 0.001
Occasional smoker 889 (8.6) 148 (11.9) 741 (10.3)
Ex-smoker 2502 (24.1) 331 (26.5) 2171 (30.0)
Never smoker 3796 (36.6) 462 (37.0) 3333 (46.1)
Physical inactivity c 3936 (46.3) 697 (55.9) 3237 (44.6) < 0.001
Mean BMI (SD) in kg/m2 24.97 (3.9) 25.13 (4.4) 24.93 (3.7) 0.1
Hazardous alcohol use 2605 (25.2) 544 (36.6) 2060 (23.3) < 0.001
Treated for psychiatric disorders 2365 (22.8) 821 (55.2) 1542 (17.5) < 0.001
Non-cardiovascular morbidity 1356 (13.1) 323 (21.7) 1026 (11.6) < 0.001
Cardiovascular diseases during follow-up 676 (6.5) 109 (7.3) 564 (6.4) 0.09
Ischemic/hypertensive heart 435 (4.2) 71 (4.8) 361 (4.1) 0.12
Stroke 298 (2.9) 53 (3.6) 245 (2.8) 0.05
aP-value using chi square test for comparison of prevalence between depressed and non-depressed
bMissing in SEP; 616 did not respond to the SEP question and did not report any routine activity
cMissing in smoking and physical inactivity = 1831; Out of these 1831, 1719 (16%) did not follow in W2, 146 did not respond to questions related to smoking and
112 did not respond to questions related to physical inactivity
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students. Participants were considered as physically in-
active if they reported exercising habitually less than three
times a week. Self-reported measures on hypertension and
diabetes mellitus were used from wave 1. They were ques-
tioned as follows; “Are you currently or have you previ-
ously been diagnosed or treated by a doctor or
hospitalized for hypertension or diabetes.” Smoking habits
were classified as regular smoker, occasional smoker, pre-
vious smoker and never smoker. Hazardous alcohol use
was assessed in W1 or W2 by the Alcohol Use Disorders
Identification Test (AUDIT) [43]. The AUDIT used a cut-
off of ≥8 for men and ≥ 6 for women to classify alcohol in-
take into hazardous alcohol intake and no hazardous
alcohol intake [44]. .Participants were considered to have
hazardous alcohol intake for the wave they scored higher
on the AUDIT.
Statistical analyses
Mean (SD) was used to report continuous variables and
frequency and percentage for categorical variables. Chi-
square test was used to assess group differences.
Imputation of missing values for MDI was done using
the mean value of the questions in the answered items.
This was done when there were missing responses for one
or two out of the 10 questions. Among those who partici-
pated in W1 or W2, if there were missing for more than
two questions, the response was left as missing (0.2% (n =
23) in W1 and 1.4% (n = 121) in W2). A trivial percentage
0.2% (n = 21) of the participants did not respond to the
questions on comorbid conditions. Smoking and physical
inactivity were measured in W2 and as 16% (n = 1719) did
not participate in W2, evidence was missing for them,
additionally 146 participants did not respond to questions
on smoking and 112 did not respond to questions on
physical inactivity. No imputations were performed for
variables other than MDI.
Cox regression models were built to estimate hazard
ratios with corresponding 95% confidence intervals. Par-
ticipants were followed from 1st of January 2001 to 31st
of December 2014 and endpoints considered were time
of IHD, stroke or death, or end of follow up. Time to
event was calculated in years = time of event (date of ad-
mission to hospital for CVD event) -start of follow-up
for those who had an event, and end of follow-up - start
of follow-up for those who did not have a cardiovascular
event. Cox regression models were adjusted for age, gen-
der and SEP in model 1 and additionally for hyperten-
sion, diabetes mellitus, smoking, physical inactivity, BMI
and hazardous alcohol intake in model 2.
Interaction was measured on an additive scale as it is ap-
propriate for assessing public health importance [45]. Four
dummy variables of depression and non-cardiovascular
morbidity were created to measure interaction. These were;
no depression and no non-cardiovascular morbidity
(reference category), depression with no non-cardiovascular
morbidity, no depression but with non-cardiovascular mor-
bidity, and depression with non-cardiovascular morbidity.
Synergy index (S) is used to measure the effect of binary
interaction among risk factors on the outcome [46] and to
determine if additive interaction was present. S = 1 means
no interaction or exactly additivity; S > 1 means positive
interaction or more than additivity; S < 1 means negative
interaction or less than additivity. S can range from 0 to in-
finity [47]. SAS 9.3 and SPSS version 19.11 and were used
for the statistical analyses.
Results
The overall prevalence of depression was 14.6% and of
non-cardiovascular morbidity 13.1%. Among those who
were depressed, 21.7% had non-cardiovascular morbid-
ity. At follow up 6.5% had a CVD diagnosis; 4.2% had is-
chemic heart diseases and 2.9% had stroke.
Distribution of the specific non-cardiovascular condi-
tions, stratified by depression status, is shown in Table 2.
The most common non-cardiovascular conditions re-
ported were respiratory disorders: 3.1%; followed by
endocrinological disorders (other than diabetes mellitus):
1.8%; and rheumatologic disorders: 1.5%. A small pro-
portion of the participants (1.6% (n = 164)) also reported
psychiatric disorders (other than depression).
Depression, as reported previously [7], and non-
cardiovascular morbidity were associated with increased
risk of CVD (HR 1.5 (95% CI 1.2, 2.0) and HR 2.0 (95%
CI 1.8, 2.6) respectively).
The interaction effect of non-cardiovascular morbidity
and depression on risk of CVD is demonstrated in
Table 3, showing hazard ratios for the combined effect
of depression and non-cardiovascular morbidity on the
risk of future CVD. Among those who were depressed
without and with non-cardiovascular morbidity, the HR
(95% CI) for future CVD were 1.4 (95% CI 1.1, 2.0) and
2.1 (95% CI 1.3, 3.4) respectively, adjusted for age, gen-
der and SEP. The associations remained statistically
significant after further adjustment for diabetes, hyper-
tension, physical inactivity, smoking, BMI and hazardous
alcohol use. The synergy index for additive interaction
was 1.5 (95% CI 1.0, 2.2) after considering all covariates.
Discussion
In this large population-based study we found that coex-
istence of depression and non-cardiovascular morbid
conditions doubled the risk of CVD. This additive inter-
action between depression and non-cardiovascular mor-
bid conditions is also supported by the synergy index.
The effect remained after adjusting for unhealthy
lifestyle factors and other previously reported cardiovas-
cular risk factors.
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Several studies demonstrate an association between
depression and CVD [7–9] as well as with other morbid
conditions [3, 6, 48]. Studies have additionally shown
that having an increased level of non-cardiovascular
morbidity worsens the outcome of cardiovascular dis-
eases like myocardial infarction and heart failure [49–
52]. .However, the results of these studies are limited by
the cross-sectional designs and have not assessed the
interplay with depression. There are some studies which
have focused on depression with specific comorbidities
leading to CVD. For example, in a longitudinal study,
patients with depression and rheumatoid arthritis were
1.4 times more likely than non-depressed rheumatoid
arthritis patients to have myocardial infraction at follow-
up [53]. To the best of our knowledge, only one previous
study has focused on depression, comorbidity and CVD.
The study included 6394 subjects who participated in
the First National Health and Nutrition Examination
Survey (NHANES I) conducted between 1971 and 1975
and later followed-up between 1982 and 1984 [54]. De-
pression and prevalent chronic medical conditions were
assessed at baseline and participants were followed up
for CVD mortality and incident medical conditions. The
results showed that having more severe depressive symp-
toms increased the risk of CVD mortality at follow-up
(HR 1.5 (95% CI 1.2, 1.8)), however the risk attenuated
when taking into account demographics, lifestyle behav-
iors, prevalent and incident chronic medical conditions
(HR 1.1 (95% CI 0.9, 1.4)). The study therefore con-
cluded that the association between depression and
CVD mortality was partially mediated by prevalent/inci-
dent comorbidity. Our study is in partial agreement with
this study, showing that depression with coexisting co-
morbidity increased the risk of CVD. The reason for
only partial agreement can be that our study mainly
assessed non-cardiovascular morbidity at baseline and
Table 2 Distribution of specific non-cardiovascular morbidity by depression status, n = 10,074
All Depressed Not depressed P value
N = 10,074 n = 1488 n = 8832
n (%) n (%) n (%)
Neurological disorders 137 (1.4) 59 (43.0) 78 (56.9) < 0.001
Endocrinological disorders (other than DM) 186 (1.8) 41 (22.0) 145 (78.0) 0.001
Respiratory disorders 312 (3.1) 82 (26.3) 230 (73.7) < 0.001
Gastrointestinal disorders
Dyspepsia 105 (1.1) 45 (42.9) 60 (57.1) < 0.001
Bowel disorders 89 (0.9) 27 (30.0) 62 (69.7) < 0.001
Liver disorders 22 (0.2) 8 (36.4) 14 (63.6) 0.002
Nephrological (kidney) disorders 97 (1.0) 25 (25.8) 72 (74.2) 0.001
Genito urinary disorders 115 (1.2) 30 (26.1) 85 (73.9) < 0.001
Tumors
Benign 36 (0.4) 09 (25.6) 27 (75.0) 0.04
Malignant 39 (0.4) 10 (25.6) 29 (74.4) 0.02
Rheumatological disorder 138 (1.5) 35 (25.4) 103 (74.6) < 0.001
Dermatological disorder 69 (0.7) 14 (20.3) 55 (79.7) 0.02
Other heart disorders (except ischemic heart diseases) 43 (0.5) 11 (25.6) 32 (74.4) 0.03
Severe infection 46 (0.5) 18 (39.2) 28 (60.8) < 0.001
Table 3 Effect of depression and non-cardiovascular morbidity on the risk of CVD, n = 10,074
Model 1a
n = 9458
HR (95% CI)
Model 2b
n = 7627
HR (95% CI)
Non-cardiovascular morbidity Non-cardiovascular morbidity
Depression No Yes No Yes
No 1 (Ref) 1.5 (1.1,2.0) 1 (Ref) 1.4 (1.0,2.0)
Yes 1.4 (1.0,2.0) 2.1 (1.4,3.4) 1.3 (1.0,2.0) 2.0 (1.1,3.3)
Synergy index (95% CI) 1.2 (0.8,1.7) 1.5 (1.0,2.2)
a Model 1 adjusted for age, gender and socioeconomic position,
b Model 2 adjusted for age, gender, socioeconomic position, diabetes, hypertension, physical inactivity, BMI, smoking and hazardous alcohol consumption
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found that its existence in the depressed increased
the incidence of CVD (HR 2.1 (95% CI 1.3–3.4)).
Additionally, there are some important differences
that make it difficult to compare results, including
differences in assessment of depression, type of co-
morbid conditions and CVD outcome. Also, we con-
sidered non-cardiovascular morbidity as an effect
modifier whereas the former study adjusted for it in
the analyses. This led to underestimation of the risks
in the former study as adjusting for comorbid condi-
tions might have accounted for most of the associ-
ation between depression and CVD. Also, the former
study included conventional CVD risk factors (e.g.
diabetes, hypertension) in their assessment of comor-
bidity, whereas we considered only non-cardiovascular
ones.
One potential explanation for our increased risk of
CVD in depressed people with coexisting non-
cardiovascular morbidity could be poorer treatment ad-
herence [55]. Lack of coordination between physicians
may contribute to patients’ non-compliance of drugs
prescribed for both comorbid and depressive conditions
[56]. Therefore, a combined, integrated clinical care and
self-management program to prevent and manage multi-
morbidity including depression is needed [57]. Also, due
to polypharmacy for different comorbid conditions,
there might be drug-drug interactions leading to adverse
clinical outcomes [58]. The underlying mechanisms
shared between depression and comorbidity leading to
CVD are not well established. Inflammation indicated by
circulating levels of interleukin-6, C-reactive protein,
and fibrinogen may be an important biological mechan-
ism through which chronic medical conditions are
linked to disorders in later life [59]. Inflammation is also
an underlying shared mechanism between depression
and CVD [60]. It might be that in depressed people, an
additional comorbid condition triggers a pathway of in-
flammation contributing to the risk of CVD [26].
The strengths of this study lie in its longitudinal design,
population-based large sample and use of validated instru-
ments for assessing depression and register-based CVD
outcomes. Our study has also some limitations that should
be acknowledged. The baseline response rate was low in
wave 1 (53%) [30, 31]. People severely affected by psychi-
atric disorders including major depression probably did
not participate and this might have led to an underestima-
tion of the magnitude of the problem and resulted in lim-
ited external validity. Hence, results cannot be generalized
to patients with severe psychiatric disorders. Although we
did have a relatively large proportion (5 .6%, n = 587) of
participants with severe depression in the PART cohort
[7], we did not have enough power to analyze a potential
dose-response relationship. One limitation is the assess-
ment of comorbidity which was based on self-reports and
hence prone to recall bias due to lack of memory and may
have resulted in non-differential misclassification thus
moving the estimates towards the null. Previous studies
have shown high validity of self-reporting for assessing co-
morbidity [61] but more objective measurements of the
comorbid conditions with objective diagnostic scales [62],
or diagnostic tests [63], could have further strengthened
the assessments and improved the validity of the study.
Since both depression and non-cardiovascular morbidity
were measured at the same point in time, we cannot clar-
ify the temporality between the two exposures. Establish-
ing temporality is a challenge as DSM-5 manual also
debates temporality and has categorized depression with
chronic conditions separately [64]. Although this study
was able to adjust for many covariates, it did not offer the
possibility to adjust for mediators like dyslipidemia, blood
glucose, type and use of antidepressants and treatment
compliance. Information on antidepressant use is import-
ant in this relation as antidepressants like tricyclic antide-
pressants are known to increase the risk of cardiac
arrhythmia which in turn may contribute to the studied
CVDs [65, 66]. However instinctive expectation of effect
decomposition of mediators might nullify the total effect
of the exposure and outcome [67]. Although we were able
to show a doubled risk for CVD when both depression
and non-cardiovascular morbidity were present, the syn-
ergy index > 1 indicated additive interaction but due to
the borderline confidence interval, the results need to be
replicated in future larger studies.
Conclusion
In this study, we showed that persons affected by de-
pression in combination with non-cardiovascular mor-
bidity had a higher risk of CVD compared to those
without non-cardiovascular morbidity or depression
alone. The additive interaction we found needs to be
replicated in future longitudinal studies and these should
also be designed to address the temporality in the occur-
rence of depression and comorbid conditions. From a
clinical perspective, future research needs to address the
identification of concomitance and to design interven-
tions encompassing simultaneous treatment of comor-
bidities and depression to prevent future CVD.
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